Lifevantage Corp. 10-Q Summary: Q1 Fiscal 2026 (Ended Sept 30, 2025)
Business Context and Reporting Period
This report covers the three-month period ended September 30, 2025 (Q1 Fiscal 2026). Lifevantage Corp. is a nutrigenomics company operating a direct sales model through independent consultants. The company sells dietary supplements (including the flagship Protandim line), skin care products, and nootropics globally. Key operational updates include the closure of the Philippines market in June 2025, the commencement of operations in Iceland in September 2025, and the acquisition of LoveBiome assets which closed on October 1, 2025.
Key Financial Metrics
| Metric | Q1 2026 (Sept 30, 2025) | Q1 2025 (Sept 30, 2024) |
|---|---|---|
| Net Revenue | $47.6 million | $47.2 million |
| Gross Profit | $37.8 million (79.5% margin) | $37.7 million (79.9% margin) |
| Operating Income | $2.3 million | $2.6 million |
| Net Income | $2.2 million ($0.17 diluted EPS) | $1.8 million ($0.14 diluted EPS) |
| Cash and Equivalents | $13.1 million | $14.6 million |
| Working Capital | $26.2 million | $23.7 million (prior period) |
| Debt Outstanding | $0 (Credit facility unused) | $0 |
Cash Flow: Net cash used in operating activities was $2.3 million, primarily due to the payment of previously accrued employee incentive compensation. Net cash used in financing activities was $4.3 million, driven by dividends ($0.6 million), stock repurchases ($0.6 million), and tax withholdings on equity awards ($3.3 million).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 0.7% year-over-year. Growth was driven by the MindBody GLP-1 System launch, offset by declines in Protandim and TrueScience product lines.
- Account Base: Total active accounts decreased 1.6% to 121,000. Active independent consultants increased 2.1% to 48,000, while active customers decreased 3.9% to 73,000.
- Product Mix: The LifeVantage product line revenue surged 133% to $9.1 million, largely due to the MindBody GLP-1 System. Conversely, Protandim revenue declined 8.8% to $22.1 million, and TrueScience revenue dropped 22.9% to $9.9 million.
- Tax Rate: The effective tax rate dropped significantly to 3.8% from 29.2% in the prior year, attributed to changes in taxable income and discrete items.
- Geographic Performance: Americas revenue grew 0.8%, while Asia/Pacific & Europe revenue grew 0.4% (driven by Japan growth and favorable currency fluctuations).
Outlook, Risks, and Unusual Items
- Acquisition: The company acquired critical assets of LoveBiome (closed Oct 1, 2025) to expand product offerings and drive revenue growth. Purchase price allocation is pending.
- Capital Allocation: The company continues its share repurchase program ($16.7 million remaining) and paid a quarterly dividend of $0.045 per share.
- Liquidity: Cash balances decreased by $7.1 million quarter-over-quarter. Management believes current cash and operating cash flows are sufficient for the next 12 months. A $5.0 million revolving credit facility is available but currently unused.
- Risks: Key risks include dependence on a few products, reliance on independent consultants, supply chain disruptions, and regulatory compliance in international markets. The company faces potential risks related to the integration of LoveBiome assets.
Investor Verification Checklist
- Revenue Sustainability: Verify if the growth in the LifeVantage line (MindBody GLP-1 System) can sustainably offset the decline in the core Protandim and TrueScience lines.
- Customer Retention: Monitor the trend of declining active customers (-3.9%) despite stable consultant numbers to assess long-term demand.
- Cash Burn: Review the $2.3 million operating cash outflow to ensure it is a one-time payment of accrued incentives rather than a structural shift in working capital needs.
- Acquisition Impact: Track the integration of LoveBiome assets and the resulting impact on future revenue and margins.
- Debt Covenants: Confirm continued compliance with the 2024 Credit Facility covenants, especially as the company utilizes the facility for potential future acquisitions.